Enzolytics Inc. (ENZC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enzolytics Inc. (ENZC) trades at $0.0006 with AI Score 39/100 (Grade D). Enzolytics, Inc. is a biotechnology company focused on developing and commercializing proprietary proteins for treating infectious diseases, particularly HIV. Market cap: $2.36M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ENZC: ENZC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENZC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENZC: 3/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Enzolytics Inc. (ENZC) Healthcare & Pipeline Overview
Enzolytics, Inc. is a drug development company specializing in proprietary proteins and monoclonal antibodies for treating infectious diseases like HIV. With clinically tested anti-HIV therapeutics and a proprietary cell line, Enzolytics aims to provide non-toxic passive immunotherapy solutions within the competitive biotechnology sector.
What Is the Investment Thesis for ENZC?
Enzolytics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing proprietary proteins and monoclonal antibodies for HIV treatment offers potential for significant growth if clinical trials are successful and regulatory approvals are obtained. Key value drivers include the successful commercialization of its anti-HIV therapeutics and the expansion of its proprietary cell line technology. However, the company faces significant challenges, including limited financial resources, competition from established pharmaceutical companies, and the inherent risks associated with drug development and regulatory approval processes. The company's negative P/E ratio of -2.98 and OTC market listing highlight the speculative nature of this investment.
Based on FMP financials and quantitative analysis
ENZC Key Highlights
- Enzolytics focuses on developing proprietary proteins for the treatment of debilitating infectious diseases.
- The company possesses patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies.
- Enzolytics has clinically tested anti-HIV therapeutics, indicating progress towards potential commercialization.
- The company has created a proprietary cell line that produces human monoclonal antibodies that target and neutralize the HIV virus.
- Enzolytics operates with a small team of 1 employee, reflecting its early-stage development.
Who Are ENZC's Competitors?
ENZC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMNDF Biomind Labs Inc. | $0.20 | +314.68% | $15.3M | 44 |
| CAIHF Chia Tai Enterprises International Limited | $0.28 | +0.00% | $217M | 53 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| SCPH scPharmaceuticals Inc. | $5.67 | +0.00% | $302M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENZC's Key Strengths?
- Proprietary technology for producing monoclonal antibodies.
- Clinically tested anti-HIV therapeutics.
- Focus on non-toxic passive immunotherapy.
- Potential for significant revenue growth if therapeutics are commercialized.
What Are ENZC's Weaknesses?
- Limited financial resources.
- Small team and limited infrastructure.
- Dependence on the success of its anti-HIV therapeutics.
- OTC market listing indicates higher risk.
What Could Drive ENZC Stock Higher?
- Publication of clinical trial results for anti-HIV therapeutics.
- Potential FDA approval for anti-HIV therapeutics.
- Development of new monoclonal antibodies for other infectious diseases.
- Pursuit of strategic partnerships with pharmaceutical companies.
- Expansion into new geographic markets.
What Are the Key Risks for ENZC?
- Financial-distress signal — its Altman Z-Score of -1.76 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for therapeutics.
- Competition from established pharmaceutical companies.
- Patent expiration and the emergence of biosimilars.
- Limited financial resources and dependence on external funding.
- OTC market listing indicates higher risk and potential for volatility.
What Are the Growth Opportunities for ENZC?
- Expansion into New Therapeutic Areas: Enzolytics could leverage its proprietary cell line technology to develop monoclonal antibodies for other infectious diseases beyond HIV. The global market for infectious disease therapeutics is substantial, offering significant growth potential. This expansion would require further research and development, but it could diversify the company's product pipeline and reduce its reliance on a single therapeutic area. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Enzolytics could pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapeutics. These partnerships could provide access to additional funding, expertise, and market access. Collaborations could also help Enzolytics expand its research capabilities and explore new therapeutic applications for its technology. Timeline: Ongoing.
- Geographic Expansion: Enzolytics could expand its geographic reach by seeking regulatory approvals and commercializing its therapeutics in new markets. The global market for HIV therapeutics is substantial, with significant unmet needs in developing countries. Expanding into new markets would require navigating different regulatory environments and establishing distribution networks, but it could significantly increase the company's revenue potential. Timeline: 2-4 years.
- Development of Diagnostic Tools: Enzolytics could leverage its expertise in monoclonal antibodies to develop diagnostic tools for infectious diseases. These diagnostic tools could be used to detect the presence of specific pathogens or to monitor the effectiveness of therapeutic interventions. The market for diagnostic tools is growing rapidly, driven by the increasing prevalence of infectious diseases and the need for accurate and timely diagnosis. Timeline: 2-3 years.
- Licensing and Out-Licensing Agreements: Enzolytics could generate revenue by licensing its proprietary technology and intellectual property to other companies. This would allow Enzolytics to monetize its assets without having to invest in the full-scale development and commercialization of its therapeutics. Licensing agreements could provide a steady stream of revenue and help fund further research and development efforts. Timeline: Ongoing.
What Opportunities Does ENZC Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Geographic expansion into new markets.
- Development of diagnostic tools.
What Threats Does ENZC Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and the risk of clinical trial failures.
- Patent expiration and the emergence of biosimilars.
- Economic downturns and changes in healthcare policy.
What Are ENZC's Competitive Advantages?
- Patented anti-HIV therapeutics provide intellectual property protection.
- Proprietary methodology for producing human IgG1 monoclonal antibodies offers a competitive advantage.
- Clinically tested therapeutics demonstrate progress towards commercialization.
- Proprietary cell line for producing human monoclonal antibodies creates a barrier to entry.
What Does ENZC Do?
Enzolytics, Inc., headquartered in Plano, Texas, is a biotechnology company dedicated to the development and commercialization of innovative protein-based therapeutics for debilitating infectious diseases. The company's primary focus is on creating treatments for HIV, leveraging its patented anti-HIV therapeutics and a unique methodology for producing human IgG1 monoclonal antibodies. These antibodies are designed to target and neutralize the HIV virus through non-toxic passive immunotherapy. Enzolytics has developed a proprietary cell line capable of producing human monoclonal antibodies, representing a significant advancement in its therapeutic approach. The company has already conducted clinical testing of its anti-HIV therapeutics, demonstrating a commitment to advancing its research and development efforts towards commercialization. Enzolytics' approach centers around providing innovative solutions for infectious diseases, marking it as a player in the biotechnology space.
What Products and Services Does ENZC Offer?
- Develop proprietary proteins for treating infectious diseases.
- Focus on commercializing anti-HIV therapeutics.
- Utilize a patented methodology for producing human IgG1 monoclonal antibodies.
- Target infectious diseases with non-toxic passive immunotherapy.
- Conduct clinical testing of anti-HIV therapeutics.
- Create a proprietary cell line that produces human monoclonal antibodies.
- Target and neutralize the HIV virus with monoclonal antibodies.
How Does ENZC Make Money?
- Develop and patent proprietary protein-based therapeutics.
- License or sell therapeutics to pharmaceutical companies or healthcare providers.
- Generate revenue through research grants and collaborations.
- Potentially manufacture and distribute therapeutics directly.
What Industry Does ENZC Operate In?
Enzolytics, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for HIV therapeutics is well-established but continues to evolve with the emergence of new treatment approaches and drug resistance. Enzolytics' focus on monoclonal antibodies and passive immunotherapy positions it within a growing segment of the market, but it faces competition from larger pharmaceutical companies with greater resources and established market presence. The company's success will depend on its ability to demonstrate the safety and efficacy of its therapeutics and secure regulatory approvals in a timely manner.
Who Are ENZC's Key Customers?
- Patients suffering from HIV and other infectious diseases.
- Pharmaceutical companies seeking novel therapeutics.
- Healthcare providers treating infectious diseases.
- Research institutions conducting infectious disease research.
Enzolytics Inc. (ENZC) Valuation Context
Valued at $2.36M, ENZC is classified as a micro-cap stock. Relative to its peer group, ENZC's quantitative score of 39/100 is below the peer average of 63/100.
ROE 0%Key Financial Metrics
Return on equity for Enzolytics Inc. stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Enzolytics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.76 places it in the distress zone, a signal of elevated financial risk.
ENZC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a strong belief in upcoming developments.
- Community sentiment has shifted positively, with many traders expressing optimism about Enzolytics' innovative approaches in the biotech sector.
- Increased media coverage highlights potential breakthroughs, generating excitement among retail investors and leading to a more favorable market perception.
- Recent presentations and updates from the company have been well-received, reinforcing the narrative of growth and opportunity.
Bear Case
- Concerns about the company's ability to secure necessary funding for ongoing projects have surfaced, leading to skepticism among some investors.
- Social sentiment reflects a divide, with a notable portion of the community voicing doubts about the sustainability of recent gains.
- Insider selling activity in the past has raised red flags, prompting caution among potential investors about the company's long-term commitment.
- Market volatility in the biotech sector has historically led to rapid sell-offs, creating an environment of uncertainty for Enzolytics' stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENZC Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Dec 13, 2019
ENZC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENZC.
Price Targets
Wall Street price target analysis for ENZC.
ENZC MoonshotScore
What does this score mean?
The MoonshotScore rates ENZC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steven Sharabura
CEO
Steven Sharabura is the CEO of Enzolytics Inc. His background includes managing the company's operations and strategic direction. Information regarding his prior experience, education, and specific credentials is not available in the provided data. As CEO, he is responsible for overseeing the development and commercialization of Enzolytics' proprietary therapeutics.
Track Record: Under Steven Sharabura's leadership, Enzolytics has focused on advancing its anti-HIV therapeutics and developing its proprietary cell line technology. Key milestones include the clinical testing of anti-HIV therapeutics. However, specific details regarding his track record and achievements are not available in the provided data.
ENZC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Enzolytics may not meet the minimum financial or reporting requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud or manipulation compared to listed stocks.
- OTC Other status indicates the company may not meet minimum financial standards.
- Potential for delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Patented anti-HIV therapeutics suggest intellectual property protection.
- Clinical testing of therapeutics indicates progress towards commercialization.
- Focus on developing innovative solutions for infectious diseases.
- Company has been in operation for several years.
- Company headquarters are located in Plano, Texas.
Common Questions About ENZC (Healthcare)
What does the AI Score mean for ENZC?
ENZC holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Enzolytics, Inc. is a biotechnology company focused on developing and commercializing proprietary proteins for treating infectious diseases, particularly HIV. The company's core assets include …
What does Enzolytics Inc. do?
Enzolytics Inc. is a biotechnology company focused on developing and commercializing proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, primarily HIV. The company's core technology revolves around its patented anti-HIV therapeutics and a unique methodology for producing human IgG1 monoclonal antibodies. These antibodies are designed to target and neutralize the HIV virus through non-toxic passive immunotherapy.
What do analysts say about ENZC stock?
As of 2026-03-16, there is no available analyst coverage or consensus on Enzolytics Inc. (ENZC) stock. This is likely due to the company's small market capitalization, OTC listing, and early stage of development. Investors should conduct their own thorough research and consider the risks associated with investing in a speculative stock with limited public information.
What are the main risks for ENZC?
Enzolytics Inc. faces several significant risks, including the inherent challenges of drug development, regulatory hurdles, and competition from established pharmaceutical companies. The company's limited financial resources and small team also pose a risk to its ability to execute its business plan.
What are the key factors to evaluate for ENZC?
Enzolytics Inc. (ENZC) holds an AI score of 39/100 (low). Not financial advice.
How frequently does ENZC data refresh on this page?
ENZC's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ENZC's recent stock price performance?
Enzolytics Inc. (ENZC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology for producing monoclonal antibodies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENZC overvalued or undervalued right now?
Enzolytics Inc. (ENZC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ENZC before investing?
Before investing in Enzolytics Inc. (ENZC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market stocks carry higher risk.
- AI analysis pending for ENZC.